Board approves Q1 results, healthcare diversification, director changes
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.7 pts more than Nifty Microcap 250 and 3.5 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q1 FY26-27 unaudited results. Consolidated revenue 2,281.82 lakhs (down about 44% YoY from 4,105.86); PBT 272.83 lakhs versus 240.93; PAT 224.34 lakhs versus 224.64. Fixed 35th AGM on September 16, 2026. Approved MoA amendment to enter healthcare, hospitals, medical devices, and pharma. Appointed Mr. Aboobaker Vattamkandathil as Independent Director; re-appointed Dr. Muhammed Swadique, Ms. Julie G Varghese, and Ms. Indu Kamala Ravindran for 5-year terms.
Revenue declined sharply YoY while margins improved; healthcare diversification plan needs shareholder nod at AGM.